Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Sales and maturities of marketable securities | 283,876 | 367,873 |
| Purchases of marketable securities | (462,461) | (274,080) |
| Acquisition of property and equipment | (4,818) | (993) |
| Net cash (used in) provided by investing activities | (183,403) | 92,800 |
| Cash flows from financing activities: | ||
| Net proceeds from stock issuances | 323,832 | — |
| Proceeds from issuance of stock from employee benefit plans | 1,152 | 265 |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's capex?
- Celldex Therapeutics (CLDX) reported capex of $3.18M in Q2 2026.
- How has Celldex Therapeutics's capex changed year-over-year?
- Celldex Therapeutics's capex increased by 336.7% year-over-year, from $728K to $3.18M.
- What is the long-term trend for Celldex Therapeutics's capex?
- Over 4 years (2021 to 2025), Celldex Therapeutics's capex has grown at a 21.4% compound annual growth rate (CAGR), from $1.25M to $2.71M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Celldex Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude